New dual-acting bronchodilator treatments for COPD, muscarinic antagonists and β2 agonists in combination or combined into a single molecule

Author： Norman Peter  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.22, Iss.12, 2013-12, pp. : 1569-1580

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pfizer's dual-acting β2 agonists/muscarinic M3 antagonists

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 18, Iss. 9, 2008-09 ,pp. : 1091-1096

Informa Healthcare

Access to resources Recommend Favorite

New long acting β2 agonists

By  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 2, 2003-02 ,pp. : 273-277

Informa Healthcare

Access to resources Recommend Favorite

New long-acting β2-agonists

By  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 9, 2004-09 ,pp. : 1385-1388

Informa Healthcare

Access to resources Recommend Favorite

Advances in Asthma and COPD Treatment: Combination Therapy with Inhaled Corticosteroids and Long-Acting &bgr;2-Agonists.

By  

Current Pharmaceutical Design, Vol. 12, Iss. 25, 2006-01 ,pp. : 3261-3279

Bentham Science Publishers

Access to resources Recommend Favorite

Long-acting β2 agonists

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 1, 2006-01 ,pp. : 99-104

Informa Healthcare

Access to resources Recommend Favorite